First-line Therapy for Patients with locally advanced or metastatic Urothelial Carcinoma A randomized, double-blind Phase-3-Study Comparing the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Lenvatinib (E7080/MK-7902) versus Pembrolizumab and Placebo as First-line Therapy for Patients with locally advanced or metastatic Urothelial Carcinoma who are not suitable for a Cisplatin-based Therapy and whose Tumors express PD-L1, as well as for Patients who are not suitable for a platinum-based Therapy regardless of the PD-L1-Expression (LEAP-011-AB 68/18 of the AUO)     «

First-line Therapy for Patients with locally advanced or metastatic Urothelial Carcinoma A randomized, double-blind Phase-3-Study Comparing the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Lenvatinib (E7080/MK-7902) versus Pembrolizumab and Placebo as First-line Therapy for Patients with locally advanced or metastatic Urothelial Carcinoma who are not suitable for a Cisplatin-based Therapy and whose Tumors express PD-L1, as well as for Patients who are not suit...     »